We observed that the presence of an intestinal isoenzyme of alkaline phosphatase (AP, EC 3.1.3.1) could be erroneously indicated by immunoprecipitation of serum samples containing a high-Mr AP isoenzyme (detennined by cellulose acetate electrophoresis) from a patient suffering from cholangiocarcinoma.
Such observations implicated a cross reaction between the high-Mr AP iSOenzyme and an antibody to intestinal AP isoenzyme. Because the antiserum we used was not absorbed, a cross reaction with a placental AP isoenzyme (1) occasionally found in serum from patients suffering from cholangiocarcinoma (2) was possible. However, no placental isoenzyme was detected by electrophoresis of the serum tested.
Several authors have shown that hepatobiliary diseases are frequently characterized by the presence of a high-Mr AP isoenzyme. Shinkai and Akedo (3) and Crofton and Smith (4) demonstrated that the isoenzyine is a part of a multi-enzyme complex of several membrane enzymes-including 5' -nucleotidase, y-glutamyltransferase, and L-leucine-aminopeptidasethat might be a fragment of the liver plasma membrane released into the blood (5). High-Mr AP is not retained on Sepharose 4B (3,6) or Sepharose 6B (7) columns. Using two chromatographic steps with DEAE-Sephacel and Sephacryl S 500 columns (4), we partly purified the high-Mr AP isoenzyme from the serum of a patient suffering from a cholangiocarcinoma. In parallel, we partly isolated the normal human liver AP isoenzyme by gradient DEAE-Sephacel and Sephacryl S 300 chromatography. We then investigated the immunological behavior of both the AP isoenzymes and the AP component isolated from the high-Mr AP complex towards commercial polyclonal anti-AP antisera: anti-AP from human liver/bone (no. 13772) and anti-AP from human small intestine (no. 13773: Merck, Darmstadt,F.R.G.),both raised in sheep.
To dissociate the AP isoenzyme from the high-Mr AP complex at room temperature, we used Nonidet P40 (NP 40) detergent (final concentration 5 mLIL), after which the released AP isoenzyme moved to the a2 position in cellulose acetate electrophoresis, i.e, the position of the liver AP isoenzyme. Electrophoresis on Pharmacia polyacrylamide gradient gel PAA 2/16(2 to 16% gradient) confirmed that the Mr of the AP isoenzyme released by NP 40 was similar to that of the liver AP isoenzyme. Similar observations have been reported by Laan et al. (9) and Crofton (10), who used Triton X-100 and sodium dodecyl sulfate. Immunoprecipitation reactions were performed with both the dissociated and the nondissociated forms of high-Mr AP isoeflzyifleand liver AP isoenzyme.
The difference between AP activities in whole serum and in the supernate after immunoprecipitation enabled us to calculate the percentage of each of the AP activities precipitated by antiintestinal and anti-liver AP antibodies (Table 1) . From these data we conclude that only the nondissociated high-Mr AP isoenzyme cross reacted with the antiserum against human intestinal AP, and that this cross reaction ceased as soon as the AP component of the enzymic complex had been released from its membrane environment. The responseof this isoenzyme to an antihuman liver AP isoenzyme antiserum was similar to that of the liver AP isoenzyme (dissociated or not). Thus, the antiserum raised against a partly purified human intestinal AP isoenzyme also recognized unspecific epitopes that were located in both intestinal and liver membranes.
The problems of cross reactivity of various forms of AP with polyclonal antisera raised against a specific isoenzyme have already been reported by Lehmann (11). Wicks et al. (12) have also described a reaction between the high-Mr AP complex and antisera to placental and liver AP.
In sera containing a fast-moving AP isoenzyme (by cellulose acetate electrophoresis), one should be cautious in interpreting results that indicate the presence of intestinal AP activity, based on immunoprecipitation with nonspecific antisera. Metabolic screening by chromatographic analysis for amino acids and organic acids in blood and urine is now commonly used as a diagnostic test in patients with neurological abnormalities and metabolic acidosis. The most frequent cause of artifacts is medication such as antibiotics (1), mucolytic agents (1), and anticonvulsants (2). Recently, we encountered another drug metabolite that gave a false-positive amino acid screening result.
Acetaminophen has become increasingly popular as a pain reliever. We have oberved a ninhydrin-reactive compound in urine specimens from patients who took this drug before urine collection. This compound migrated to a locationnear dihydroxyphenylalanme (roPA) in the system of two-dimensional separation of amino acids by high voltage electrophoresis at pH 1.6 (6% formic acid) followed by ascending solvent chromatography in butanoll acetic acid/water In the two-dimensional paper-chromatographic system, this metabolite can be differentiated from dihydroxyphenylalanine by its positive reaction to iodoplatinate reagent. It can also be distinguished from two other sulfurcontaining compounds, which migrate to nearby locations, N-acetylcysteinecysteine disuffide (from a mucolytic inhalant) (1) and /3-mercaptolactatecysteine disulfide (excreted by patients with /3-mercapto-pyruvate sulfur transferase deficiency) (1), by a negative cyanide-nitroprusside test for these disulfides. When urinary amino acids are measured by an analyzer, it is important that this drug metabolite be distinguished from phenylalanine, which is excreted by patients with phenylketonuria.
